Veracyte VCYT Testing revenue — Allocation of facilities and IT expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept vcyt:CostOfRevenueAllocationOfFacilitiesAndInformationTechnologyExpenses.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's testing revenue — allocation of facilities and it expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's testing revenue — allocation of facilities and IT expenses?
- Veracyte (VCYT) reported testing revenue — allocation of facilities and IT expenses of $2.96M in Q1 2026.
- How has Veracyte's testing revenue — allocation of facilities and IT expenses changed year-over-year?
- Veracyte's testing revenue — allocation of facilities and IT expenses decreased by 12.1% year-over-year, from $3.37M to $2.96M.
- What is the long-term trend for Veracyte's testing revenue — allocation of facilities and IT expenses?
- Over 3 years (2022 to 2025), Veracyte's testing revenue — allocation of facilities and IT expenses has grown at a 33.1% compound annual growth rate (CAGR), from $5.76M to $13.58M.
- What does testing revenue — allocation of facilities and IT expenses mean?
- This represents the portion of corporate facilities, infrastructure, and information technology costs allocated to the diagnostic testing segment. It reflects the indirect overhead burden required to support the physical and digital laboratory environment.